Emyria Ltd's (ASX:EMD) Dr Michael Winlo talks Proactive's Andrew Scott through its March quarterly update. He says the company's well positioned to commence its pivotal clinical trials - the important first steps towards successful registration of an over-the-counter CBD product with the TGA. Winlo adds that they're also advancing the EMD-004 program - targeting irritable bowel syndrome and scoping pipeline expansion therapeutically (with psychedelic-assisted therapy) and geographically (FDA pathways).
Emyria focused on initiating and completing pivotal clinical trials for EMD-003
